Business
Daré Bioscience to Participate in Two Upcoming Conferences: 2023 BIO International Convention and the Longwood Healthcare Leaders Spring 2023 MIT Conference
SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina
About this update from Dare Bioscience, Inc.
[{"type":"text","content":"SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in two conferences during the week of June 5th: BIO International Convention, being held June 5-8, 2023 at the Boston Convention and Exhibition Center in Boston, MA. Ms. Johnson will provide a corporate overview on Tuesday, June 6th at 12:00 p.m. EDT.Longwood Healthcare Leaders Spring 2023 MIT Conference, being held June 7-8, 2023 at the Koch Institute at MIT, Cambridge, MA. Ms. Johnson will participate in a panel discussion on Thursday, June 8th at 3:40 p.m. EDT: NAVIGATING REGULATORY CHALLENGESMike Curtis, CEO, eGenesisRachelle Jacques, CEO, AkariSabrina Johnson, CEO, Daré BioscienceModerator: Jocelyn Ulrich, Deputy Vice President, Policy & Research, PhRMA Members of the company’s management team will be available for one-on-one meetings during the BIO International Convention. Persons attending the convention who are interested in meeting with Daré management may request a meeting through the BIO One-on-One Partnering™ system. The Longwood Healthcare Leaders conference is by invitation only. About Daré Bioscience Daré Bioscience is a biopharmaceutical company committed to advancing innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, vaginal health, reproductive health, menopause, sexual health and fertility. Daré’s first FDA-approved product, XACIATO™ (clindamycin phosphate) vaginal gel, 2% is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. XACIATO is a clear, colorless, viscous gel, to be administered once intravaginally as a single dose. Daré’s portfolio also includes potential first-in-category candidates in clinical development: Ovaprene®, a novel, hormone-free monthly intravaginal contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female...